Skip to content

Efficacy of the Cognitive Training Based on Location Information and Activity in People With Mild Cognitive Impairment

Efficacy of the Cognitive Training Based on Location Information and Activity in People With Mild Cognitive Impairment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03928613
Enrollment
43
Registered
2019-04-26
Start date
2019-04-17
Completion date
2020-02-28
Last updated
2020-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Keywords

Cognitive training, Cognitive intervention, Cognitive rehabilitation

Brief summary

The purpose of this study is to examine therapeutic efficacy of cognitive Training based on location information and activity in people with mild cognitive impairment

Detailed description

* A single arm, open-label study. * Cognitive Training based on location information and activity is consists of both cognitive training and exercise(walking) using objects in the participant's home. The researchers visit the participant's home and find objects that were mainly used in the real life and easy to access (table, computer, television, etc.) and attach the recognition Bluetooth Low Energy(BLE) Tag (sticker integrated). The stickers printed on the tags consist of word categories (eg animals) belonging to a particular category, so as to assist strategic recall in the stepped recall task. The participants follow the instruction from the tablet-based program to perform the task. During performing the cognitive training program, the participants are guided to walk between the tagged objects in their home. * The participants are aged over 60 years old and diagnosed with mild cognitive impairment.

Interventions

BEHAVIORALtablet based Cognitive Training based on location information

Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks

Sponsors

Institute of Information & Communications Technology Planning & Evaluation, Korea
CollaboratorUNKNOWN
Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged above 60 * Confirmed literacy o Diagnosed with mild cognitive impairment by International Working Group on Mild Cognitive Impairment and Clinical Dementia Rating(CDR) of 0 or 0.5.

Exclusion criteria

* Evidence of delirium, confusion * Any neurological conditions causing cognitive decline such as Parkinson's disease, brain hemorrhage, brain tumor, normal pressure hydrocephalus * Evidence of severe cerebrovascular pathology * Presence of depressive symptoms that could influence cognitive function * Presence of medical comorbidities that could result in any difficulties in study participation

Design outcomes

Primary

MeasureTime frameDescription
Change in CERAD-TS1 scorebaseline and 6 weeksTotal Score of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Assessment Battery (CERAD-TS1) . CERAD-TS1 is generated by simply summing the scores of six tests including the 1) Verbal fluency (range 0-24), 2) Boston naming test (0-15), 3) Word List Memory (0-30), 4) Word List Recall (0-10), 5) Word list recognition (0-10), 6) Constructional Praxis (0-11). The range of CERAD-TS1 score is 0 to 100 points), and the higher score represents the better cognitive function.

Secondary

MeasureTime frameDescription
Change in MMSE scorebaseline and 6 weeksMini-Mental State Examination (MMSE), ranged 0-30, the higher score represents the better cognitive function
Change in SMCQ scorebaseline and 6 weeksSubjective Memory Complaint Questionnaire (SMCQ), ranged 0-14, the higher score represents the more difficulties in memory function for everyday life
Change in GDS scorebaseline and 6 weeksGeriatric depression scale (GDS), ranged 0-30, the higher score represents the more severe depressive symptoms

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026